Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;44(10-12):e70104.
doi: 10.1002/sim.70104.

A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events

Affiliations

A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events

Thomas R Fleming et al. Stat Med. 2025 May.

Abstract

In randomized clinical trials, stopping study medication, use of rescue treatment, and other intercurrent events can complicate interpretation of results. The ICH E9(R1) Addendum on estimands stimulated important cross-disciplinary discussions on trial objectives. Unfortunately, with influence of the Addendum, many trials have proposed analyzing primary endpoints using "while on treatment", "hypothetical", or "principal stratum" strategies that handle intercurrent events in ways that use post-randomization outcomes to exclude information from randomized participants and don't preserve integrity of randomization, or that don't reliably capture the intervention's meaningful net effects. These approaches have inherent limitations in ability to draw scientifically rigorous inference on clinically relevant causal effects important for decisions about adopting interventions. We describe advantages of trials with standard-of-care control arms targeting estimands using "treatment policy" approaches for intercurrent events, while potentially incorporating other meaningful intercurrent events, such as death, into the primary endpoint applying a composite strategy. Well-designed and -conducted trials targeting such estimands achieve scientifically rigorous causal inference through analyzes that protect the integrity of randomization. Such estimands also provide meaningful information relevant to real-world settings because they (1) are unconditional in nature i.e., they don't condition on post-treatment circumstances that might not be many participants' experiences; and (2) properly evaluate the experimental intervention within a regimen that includes possible ancillary care that would be clinically appropriate in real-world settings. We hope to add clarity about appropriate strategies for intercurrent events and how to improve design, conduct, and analysis of clinical trials to address questions of greatest clinical importance reliably.

Keywords: causal inference; estimands; intercurrent events; randomization.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

References

    1. European Medicines Agency , ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials (ICH, 2020).
    1. National Research Council (US) Panel on Handling Missing Data in Clinical Trials , The Prevention and Treatment of Missing Data in Clinical Trials (National Academies Press, 2010), 162. - PubMed
    1. Friedman L. M., Furberg C. D., DeMets D. L., Reboussin D. M., and Granger C. B., Fundamentals of Clinical Trials, 5th ed. (Springer, 2015), 550.
    1. Rothwell R., Nikolov N. P., Maynard J. W., and Levin G., “Noninferiority Trials to Evaluate Drug Effects in Rheumatoid Arthritis,” Arthritis & Rhematology 72, no. 8 (2020): 1258–1265. - PubMed
    1. DeMets D. L., Psaty B. M., and Fleming T. R., “When Can Intermediate Outcomes Be Used as Surrogate Outcomes?,” Jama 323, no. 12 (2020): 1184–1185. - PubMed

MeSH terms

LinkOut - more resources